skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Jeffrey Mandel (a director on Covalon's Board) sent one of his periodic e-mails directly to COV investors. Today's message included a PDF attachment of a 25pp research document COV apparently commissioned from Zacks Small Cap Research in Chicago. Unsurprisingly, the analysis is glowing, which stated, in part, "We forecast Covalon to generate revenue and EPS of C$53.4M and C$0.13 in 2019 and C$64.5M and C$0.30 in 2020. We value Covalon using a combination of P/S and P/E methodologies. Based on analyst's revenue and EPS estimates of publicly traded companies in focused on wound care and medical supplies, infection control and vascular products, we calculate fair value of Covalon at ~C$11.2/share, or US$8.50 based on current exchange rates."
Read Answer Asked by RANDALL on April 01, 2019
Q: Publish on public side if you like. I realize your question platform is not a place for discussions (forum is).
The other day a gentleman indicated that RBCDI converts and re-converts a US div, thus losing $ to fees. I invest at RBCDI so investigated my US holdings (held on US side of acct) that are div payers. I do not believe his info is correct. For ex, I held 362 shares of STZ in RSP, and they paid 0.74USD as a Cl A share div (from STZ website). $267.88 USD was credited to my acct, then the DRIP, I ended with 363 shares. I investigated a few US holdings, and a number of txns. All the same story. Point: Important to do own DD.
Read Answer Asked by Bob on April 01, 2019
Q: Hi, from a recent Globe article (excerpt below) it appears a substantial activist shareholder group is taking issue with the deal announced with BEP. Do you feel it has the potential to derail the Deal or substantially modify it. So far the market has not reacted to this news. Thanks.

“However, Mangrove Partners, Bluescape Energy Partners and Cove Key Management LP rejected the deal earlier this week for leaning too heavily in favour of Brookfield, and said they would nominate five directors to TransAlta’s 10-member board with the aim of being able to terminate the investment.

On Friday, the investors – which own a combined 10.1 per cent of TransAlta’s outstanding shares – issued a statement calling on TransAlta to release more details on its decision to side with Brookfield, which it called a “rushed process.”

Spokespersons at TransAlta and Brookfield declined to comment.

“Let me be clear: Our goal is not to stop this transaction, but rather to ensure that the company retains the option to pursue or renegotiate a better one," Mangrove Partners’ Mr. August said.”
Read Answer Asked by Gary on April 01, 2019
Q: Many of the analysts appearing on BNN seem cautionary about the market and suggest investors hold some cash in their portfolios.
In my opinion at the present time of the three 5I portfolios, the Finance portfolio is the most attractive and offers some very decent dividends. Your thoughts would be appreciated. Thanks, Bill
Read Answer Asked by William J on April 01, 2019
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!